Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip

NCT00541489 is registered in ClinicalTrials.gov with NicOx as lead sponsor.

NCT NCT00541489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00541489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip
Lead sponsor
NicOx
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
Not reported
Enrollment
800 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, osteoarthritis, hip